TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05133193
Drug: three kinds of antibiotics
Normalized name: three-lobe sage extract
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
Study: NCT02300753
Drug: EPI-743
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-743 is a quinone oxidation product of alpha-tocotrienol
Study: NCT04865250
Drug: Atezolizumab 1200 mg abs day 1 q22 (iv)
Normalized name: atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
Study: NCT05738694
Drug: Axitinib plus Toripalimab
Normalized name: Toripalimab
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
Study: NCT05136378
Drug: Low Dose Selenious Yeast Tablets
Normalized name: Selenious Acid
DrugBank: Yeast (DB11017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Selenious Yeast Tablets
Study: NCT05136378
Drug: High Dose Selenious Yeast Tablets
Normalized name: Selenious Acid
DrugBank: Yeast (DB11017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Selenious Yeast Tablets
Study: NCT05464862
Drug: Popliteal Plexus Block with 10 ml
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
Study: NCT05464862
Drug: Popliteal Plexus Block with 20 ml
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
Study: NCT05464862
Drug: Popliteal Plexus Block with 30 ml
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
Study: NCT05464862
Drug: Femoral Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
Study: NCT05464862
Drug: Sciatic Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
Study: NCT04350190
Drug: Apatinib mesylate tablet
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.
Study: NCT04350190
Drug: PD-1
Normalized name: NPD-1
DrugBank: PD-168393 (DB07662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
Study: NCT00000993
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06070740
Drug: Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators.
Study: NCT06324279
Drug: Misoprostol 200mcg Tab
Normalized name: MISOPROSTOL 200MCG TAB
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction of labor by misoprostol
Study: NCT06736691
Drug: emodepside (BAY 44-4400)
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with single dose of oral 15 mg emodepside
Study: NCT06736691
Drug: matching placebo of emodepside
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with single dose of oral emodepside matching placebo
Study: NCT06736691
Drug: Mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
Study: NCT06736691
Drug: similar placebo to mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
Study: NCT06738303
Drug: Cabazitaxel and carboplatin
Normalized name: Cabazitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06738303
Drug: Lu-PSMA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05138887
Drug: Tetrahydrobiopterin
Normalized name: tetrahydrobiopterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
Study: NCT06737731
Drug: SHR-1681
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
Study: NCT05429229
Drug: Lagricel PF®
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
Study: NCT06738277
Drug: Bmab 1200 (Biosimilar Ustekinumab)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose
Study: NCT06029907
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive varenicline prescribed by their oncologist
Study: NCT05538624
Drug: AVB-001 (Dose Escalation Phase)
Normalized name: peanut allergenic extract
DrugBank: AVB-001 (DB18452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
Study: NCT05538624
Drug: AVB-001 (Dose Expansion Phase)
Normalized name: ethanol
DrugBank: AVB-001 (DB18452)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
Study: NCT05942911
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
Study: NCT05942911
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
Study: NCT05480098
Drug: Brimonidine Topical
Normalized name: brimonidine topical
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical brimonidine intraoperatively for hemostasis
Study: NCT06735391
Drug: JMT101
Normalized name: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
DrugBank: Becotatug (DB19069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.
Study: NCT06735391
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EGFR TKI
Study: NCT06736262
Drug: Briquilimab
Normalized name: Briquilimab
DrugBank: Briquilimab (DB18136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional details needed
Study: NCT06734481
Drug: Sodium bicarbonate pleural lavage
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days. For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage.Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days.
Study: NCT05554237
Drug: PF-07612577
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07612577
Study: NCT05554237
Drug: PF-06264006
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06264006
Study: NCT06066060
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin,administered orally
Study: NCT05638763
Drug: Dasatinib Pill
Normalized name: dasatinib Pill
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year
Study: NCT05638763
Drug: Ketoconazole Pill
Normalized name: ketoconazole Pill
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive ketoconazole 200mg two times a day, orally, for one year.
Study: NCT06409702
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued
Study: NCT06409702
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued
Study: NCT06409702
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression
Study: NCT06409702
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8
Study: NCT06449833
Drug: Henagliflozein and Metformin
Normalized name: metformin and canagliflozin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The experimental group will be treated with 10mg Henagliflozein and Metformin.
Study: NCT06449833
Drug: Linagliptin and Metformin
Normalized name: Linagliptin and metformin only product
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The control group will be treated with 5mg Linagliptin and Metformin.
Study: NCT06110923
Drug: CKD-846
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once administration of Investigational Product
Study: NCT06409702
Drug: VRD for first-cycle induction therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。
Study: NCT05102149
Drug: PB-201
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-201: 100 mg each time, orally in the morning and evening respectively;
Study: NCT05102149
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
Study: NCT05102149
Drug: Vildagliptin matched placebo
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: One tablet each time, orally in the morning and evening respectively;
Study: NCT05644379
Drug: Cadonilimab Injection
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
Study: NCT05644379
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 80mg, po, orally once daily
Study: NCT02590523
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral vancomycin injection during cataract surgery
Study: NCT02590523
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral moxifloxacin injection during cataract surgery
Study: NCT05700955
Drug: Pembrolizumab and Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
Study: NCT00000875
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000875
Drug: Diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000875
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000875
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000875
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06224452
Drug: ibrutinib exposure
Normalized name: Ibrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose
Study: NCT04841720
Drug: Metformin Hydrochloride tablet
Normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);
Study: NCT04841720
Drug: HSK16149+Metformin（phase 3）
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.
Study: NCT06426199
Drug: Chitosan-Hyaluronate Gel Mixture
Normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Chitosan-Hyaluronate Gel Mixture into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
Study: NCT06426199
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Hyaluronic acid into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
Study: NCT01689376
Drug: Regorafenib (BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
Study: NCT04695223
Drug: Arsenic Trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
Study: NCT05518929
Drug: Ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sedation of gastrointestinal endoscopy with Ciprofol
Study: NCT05518929
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The sedation of gastrointestinal endoscopy with Propofol
Study: NCT05242445
Drug: Cetrelimab
Normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
Study: NCT04511026
Drug: Lymphoseek
Normalized name: Lymphoseek
DrugBank: Tilmanocept (DB15373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive diagnostic agent
Study: NCT04511026
Drug: Indocyanine Green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
Study: NCT00353964
Drug: rEV131
Normalized name: REV131
DrugBank: REV131 (DB05032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00353964
Drug: Prenisolone sodium phosphate 1.0%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00353964
Drug: rEV131 vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
DrugBank: REV131 (DB05032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06373042
Drug: Intraarterial and intravenous tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial and intravenous tirofiban after endovascular thrombectomy
Study: NCT05027516
Drug: Rocephin
Normalized name: Rocephin
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
Study: NCT05949606
Drug: SI-B001
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05949606
Drug: SI-B003
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT04848454
Drug: Camrelizumab with vinorelbine and cisplatin
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
Study: NCT06735443
Drug: Bupivacaine with Dexmetedomidine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.